Introduction

Worldwide prevalence of obesity has been on the rise, along with its dreaded health consequences: diabetes, vascular diseases, and hypertension (1, 2). Obesity is due to a mismatch between caloric intake and energy expenditure in susceptible individuals. Redundant molecular and neural mechanisms control energy and glucose homeostasis (3–9). Among them, the integration of nutritional cues within the hypothalamus is emerging as a critical step in the metabolic and behavioral adaptation to changes in energy balance. The hypothalamic metabolism of fatty acids can profoundly modify feeding behavior and glucose metabolism (10–13) and has been proposed to function as a biochemical sensor for nutrient availability. The hypothalamic metabolism of fatty acids can profoundly modify feeding behavior and glucose metabolism (10–13) and has been proposed to function as a biochemical sensor for nutrient availability that in turn exerts negative feedback on nutrient intake (13, 14) and glucose production (10, 15–17). In this regard, the hypothalamic levels of long-chain fatty acyl-CoAs (LCFA-CoAs) can be increased by enhanced esterification of circulating or central lipids (10, 16) and/or by the local inhibition of lipid oxidation (18). These interventions also result in marked inhibition of feeding behavior and liver glucose fluxes (10, 15, 16, 18) (Figure 1A).

Sprague-Dawley rats presented with a highly palatable (lard-supplemented) diet promptly double their daily caloric intake and develop severe hepatic insulin resistance within just 3 days (19, 20). In this model the central administration of the long-chain fatty acid (LCFA) oleic acid fails to decrease food intake and glucose production (21). Is defective sensing of lipids within the hypothalamus partly responsible for the defective behavioral and metabolic adaptation in this model? Here we postulated that a critical biochemical underpinning for these defects is that an increase in lipid availability fails to increase the hypothalamic levels of LCFA-CoAs. The associated impairment in hypothalamic nutrient sensing in turn contributes to the susceptibility to obesity and insulin resistance in response to voluntary overfeeding. Consistent with this postulate, rescuing the nutritional regulation of hypothalamic LCFA-CoA levels should restore energy and glucose homeostasis by reinstating this central signal of nutrient abundance (Figure 1A).

To address this hypothesis we used molecular and pharmacologic inhibition of the liver isof orm of carnitine palmitoyltransferase-1 (CPT1A; Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI26640DS1) as experimental tools designed to increase the hypothalamic levels of LCFA-CoAs in overfed (OF) rats to the levels observed in rats fed a standard chow (SC) rats. These experimental manipulations allowed us to examine whether restoring hypothalamic lipid sensing in OF rats is sufficient to curtail food intake and liver glucose fluxes and to restore the responses to an acute increase in lipid availability. Here we show that inhibition of lipid oxidation within the hypothalamus is sufficient to restore lipidsensing and to suppress food intake and hepatic glucose production.

Results

Short-term overfeeding impairs hypothalamic lipid sensing. We postulated that a defect in hypothalamic lipid sensing accounts at least in part for persistent hyperphagia and for the rapid onset of hepatic insulin resistance following short-term voluntary overfeeding. To examine the impact of a physiological increase in circulating lipids on the mediobasal hypothalamus (MBH) levels of LCFA-CoAs, we placed chronic catheters in rats and then infused a lipid emulsion designed to double plasma LCFA levels (Figure 1, B and C). As previously reported, the increase in circulating LCFA resulted in an approximately 2-fold increase in the MBH levels of LCFA-CoAs in SC rats.
research article

(Figure 1D; lipid versus saline in SC). Conversely, a similar increase in circulating lipids failed to significantly increase LCFA-CoA levels in the MBH of OF rats (Figure 1D; lipid versus saline in OF).

In order to delineate whether this observation was due to defective transfer of LCFA across the blood-brain barrier or to alterations in cellular fatty acid metabolism, we next infused oleic acid directly within the MBH of SC and OF rats (Figure 1E). The MBH infusion of this LCFA markedly increased the MBH levels of oleyl-CoA in SC rats but failed to increase MBH oleyl-CoA levels in OF rats. This finding is consistent with (and may account for) the lack of anorectic and metabolic effects of central lipid, MBH oleic acid, or respective vehicle controls (see Methods). (C) Experimental protocol for lipid infusion. (D) Total LCFA-CoA and oleyl-CoA levels in the MBH in SC and OF rats following 4 hours of saline (Sal) or lipid infusion (LI). (E) Oleyl-CoA levels in the MBH in SC and OF rats following 6 hours of vehicle (10% hydroxypropyl-ß-cyclodextrin) or oleic acid (OA) infusion. *P < 0.05 versus Sal.

isoforms of CPT1, the muscle isoform encoded by the CPT1B gene and the liver isoform encoded by the CPT1A gene. The latter is the prevalent isoform in the arcuate (Figure 2A). Short-term overfeeding did not increase the expression of either CPT1 transcript in the arcuate, suggesting that the increased enzymatic activity is likely due to increased protein stability rather than to increased gene expression (Figure 2A). The cellular level of malonyl-CoA, a potent endogenous inhibitor of CPT1, largely determines the in vivo activity of CPT1A. To further examine potential mechanisms responsible for the increased turnover of LCFA-CoAs in the MBH of OF rats, we next measured the MBH levels of malonyl-CoA as well as the protein expression of key enzymes involved in its metabolism. Acetyl-CoA carboxylase (ACC) catalyzes the formation of malonyl-CoA from acetyl-CoA (Figure 1A), and its activity is decreased by phosphorylation. ACC phosphorylation (pACC) was markedly increased in the MBH of OF compared with that of SC rats (Figure 2B). Consistent with this finding, the MBH levels of malonyl-CoA were approximately 70% lower in OF than in
SC rats (Figure 2C). On the other hand, we could not detect significant changes in the MBH expression of AMP-activated protein kinase (AMPK) and fatty acid synthase nor in the phosphorylation of AMPK (Supplemental Figure 2A). Taken together, these observations raise the possibility that decreasing oxidative metabolism of LCFAs within the MBH could restore hypothalamic lipid sensing and curtail feeding behavior in OF rats (Figure 1A).

Inhibition of hypothalamic CPT1A activity decreases food intake in OF rats. Central inhibition of CPT1A activity is sufficient to decrease food intake and body weight in nonobese rats (18). We hypothesized that this anorectic effect is preserved in OF rats and may be sufficient to normalize energy balance. In order to test this hypothesis, we used genetic and pharmacologic approaches designed to curtail the oxidative metabolism of LCFAs-CoAs in the MBH of OF rats (Supplemental Figure 1, B and C, and Figure 3A) in the hope of amplifying the signal generated by an increase in lipid availability (Figure 1A). Thus we first examined whether MBH inhibition of CPT1A activity decreases food intake following 3 days of voluntary overfeeding in male Sprague-Dawley rats. To this end, we infused SC and OF rats icv with a reversible inhibitor of CPT1A activity (Supplemental Figure 1B). As expected the icv administration of the CPT1A inhibitor markedly decreased food intake in SC rats (Figure 3B) (18). Importantly, a similar effect of central CPT1A inhibition was also observed in OF rats (Figure 3C). Indeed, the high dose of the CPT1A inhibitor decreased daily caloric intake in OF rats by approximately 40%, to levels (84 ± 11 kcal) that were similar to those of vehicle-treated SC rats (73 ± 8 kcal; Supplemental Figure 3, A and C).

Inhibition of hypothalamic CPT1A expression decreases food intake in OF rats. We next examined whether silencing the expression of the CPT1A gene (Figure 3, D and E, and Supplemental Figure 3) can reproduce the anorectic effects elicited by the pharmacologic inhibition of hypothalamic CPT1A activity. To this end we injected icv a plasmid containing a ribozyme that specifically cleaves CPT1A mRNA (CPT1A-Ribo; Supplemental Figure 1C). Treatment with this ribozyme selectively decreases the expression of CPT1A, but does not alter the expression of CPT1B and that of numerous

### Table 1

<p>| Table 1 Pharmacologic inhibition of hypothalamic CPT1A: general characteristics before and during pancreatic insulin clamp |
|-------------|-----------|-----------|-----------|-----------|-----------|</p>
<table>
<thead>
<tr>
<th>n</th>
<th>SC control</th>
<th>SC CPT1Ai</th>
<th>PF control</th>
<th>PF CPT1Ai</th>
<th>OF control</th>
<th>OF CPT1Ai</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>306 ± 1</td>
<td>301 ± 6</td>
<td>300 ± 8</td>
<td>304 ± 3</td>
<td>311 ± 5</td>
<td>317 ± 9</td>
</tr>
<tr>
<td>Food intake (kcal)</td>
<td>73 ± 3</td>
<td>74 ± 3</td>
<td>77</td>
<td>77</td>
<td>77</td>
<td>77</td>
</tr>
<tr>
<td>Glucose (mM)</td>
<td>8.2 ± 0.9</td>
<td>8.4 ± 0.2</td>
<td>8.2 ± 0.4</td>
<td>8.3 ± 0.1</td>
<td>8.2 ± 0.5</td>
<td>8.3 ± 0.3</td>
</tr>
<tr>
<td>Insulin (ng/ml)</td>
<td>1.2 ± 0.3</td>
<td>1.1 ± 0.2</td>
<td>1.2 ± 0.1</td>
<td>0.9 ± 0.3</td>
<td>1.4 ± 0.2</td>
<td>1.3 ± 0.3</td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>0.9 ± 0.2</td>
<td>0.9 ± 0.1</td>
<td>0.8 ± 0.0</td>
<td>1.1 ± 0.1</td>
<td>1.3 ± 0.3</td>
<td>1.4 ± 0.2</td>
</tr>
<tr>
<td>FFA (mM)</td>
<td>0.6 ± 0.1</td>
<td>0.5 ± 0.2</td>
<td>0.6 ± 0.1</td>
<td>0.7 ± 0.2</td>
<td>0.8 ± 0.1</td>
<td>0.7 ± 0.1</td>
</tr>
<tr>
<td>Clamp</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (mM)</td>
<td>7.8 ± 0.3</td>
<td>8.1 ± 1.1</td>
<td>7.7 ± 0.2</td>
<td>7.8 ± 0.2</td>
<td>7.9 ± 0.4</td>
<td>7.9 ± 0.2</td>
</tr>
<tr>
<td>Insulin (ng/ml)</td>
<td>0.8 ± 0.1</td>
<td>0.9 ± 0.1</td>
<td>0.9 ± 0.1</td>
<td>0.9 ± 0.1</td>
<td>0.9 ± 0.1</td>
<td>0.9 ± 0.1</td>
</tr>
<tr>
<td>FFA (mM)</td>
<td>0.5 ± 0.1</td>
<td>0.6 ± 0.1</td>
<td>0.5 ± 0.1</td>
<td>0.6 ± 0.1</td>
<td>0.6 ± 0.0</td>
<td>0.7 ± 0.1</td>
</tr>
</tbody>
</table>

Data are means ± SEM. The values during clamp represent steady-state levels. Food intake and body weight were measured at the beginning of the clamp. FFA, free fatty acids; HF-CR, calorie intake matched to the group receiving SC with high fat diet; CPT1A, CPT1A inhibitor. *P < 0.05 versus SC and PF.
other transcripts and proteins (18). Rats were divided into SC and OF groups and fed the corresponding diets for 2 days (Figure 3A). Prior to icv injections, OF rats markedly increased their daily caloric intake compared with SC rats (Table 1). On the third day, each group received a single icv injection of CPT1A-Ribo or a control vector, and daily food intake was monitored for 72 hours. Injection of the CPT1A-Ribo icv significantly decreased CPT1A expression and total CPT1 activity in the arcuate nucleus of both SC and OF rats (Figure 3, D and E). CPT1A-Ribo treatment markedly decreased food intake and body weight gain in SC (Figure 3F) as well as in OF rats (Figure 3G), while their respective control vectors had no discernible effects on these parameters. The anorectic effect of a single injection of CPT1A-Ribo was sustained for at least 2 days (Figure 3, F and G). As observed with the pharmacologic inhibition, normalizing CPT1 activity within the MBH via transient silencing of CPT1A expression was sufficient to decrease the daily caloric intake of OF rats to the level of SC rats (Supplemental Figure 3). Thus, although the central administration of LCFA failed to decrease food intake in this model (21), inhibition of lipid oxidation within the MBH is sufficient to restore energy balance in OF rats.

Figure 3
Inhibition of hypothalamic CPT1A activity or expression decreases food intake. (A) Schematic representation of the feeding experiments. (B and C) Daily changes in food intake and body weight induced by icv administration of 2 doses of the CPT1A inhibitor or of its inactive stereoisomer in SC and OF rats. (D and E) Arcuate CPT1 activity and CPT1A expression in arcuate nucleus of SC and OF rats treated with CPT1A-Ribo or vector. (F and G) Changes in food intake and body weight induced by icv administration of CPT1A-Ribo or vector in SC and OF rats. *P < 0.05 versus control and day 0.
Potential mechanisms of hyperphagia in OF rats. Among the downstream MBH targets of the main anorexigenic hormone leptin are the serine/threonine kinase AMPK (14) and the suppressor of cytokine signaling-3 (SOCS3) (22). Leptin decreases the phosphorylation and activity of AMPK in the arcuate, and this effect appears to be required for its anorexigenic effect (14). Short-term overfeeding failed to alter the expression and phosphorylation of AMPK in the MBH (Supplemental Figure 2A). SOCS3 is a potent inhibitor of leptin signaling and is emerging as an important determinant of leptin resistance in models of chronic obesity (23). However, we did not observe an increase in SOCS3 expression in the MBH of OF rats (Supplemental Figure 2B). To gain insight into potential mechanisms responsible for the changes described above in the feeding behavior of OF rats, we next analyzed the effect of overfeeding and central CPT1A inhibition on the gene expression of the orexigenic neuropeptides neuropeptide Y (NPY) and agouti-related peptide (AGRP). OF rats showed a significant increase in AGRP and NPY mRNA. Importantly, these increases were negated by the icv infusion of the CPT1A inhibitor (Supplemental Figure 3B). Importantly, central inhibition of CPT1 did not display any effect on conditioned taste aversion Supplemental Figure 2C).

Inhibition of hypothalamic CPT1A activity restrains liver glucose fluxes in OF rats. Insulin and LCFAs act in the MBH to inhibit liver glucose production (10, 16, 18, 24). However, short-term overfeeding leads to impairment of hepatic insulin action (20) as well as resistance to the effects of LCFAs on liver glucose fluxes (16, 21). Since in SC rats the central inhibition of CPT1A activity restrains liver glucose fluxes independently of CPT1A's effects on energy balance (18), we next examined whether this intervention can reverse the hepatic insulin resistance induced by short-term overfeeding. To this end we combined the icv infusion of the CPT1A inhibitor or its inactive stereoisomer with pancreatic insulin clamp studies designed to maintain plasma insulin concentration at basal levels (Figure 4, A and B). To discern the relative contributions of the increased caloric intake versus the macronutrient composition of the test diets, we also included a group of rats receiving a fixed daily amount of the high-fat diet designed to match the daily caloric consumption of the SC rats (pair-fed [PF] group; Table 1). When the inactive stereoisomer was infused icv, marginal rates of glucose infusion were required to maintain euglycemia in the 3 experimental groups (SC, 1.9 ± 0.7 mg/kg/min; PF, 1.7 ± 0.3 mg/kg/min; and OF, 0.4 ± 0.2 mg/kg/min). On the other hand, when the CPT1A inhibitor was infused icv, the rate of glucose infusion required to maintain euglycemia was significantly lower (SC, 1.9 ± 0.7 mg/kg/min; PF, 1.7 ± 0.3 mg/kg/min; and OF, 0.4 ± 0.2 mg/kg/min).
lycemia was markedly and similarly increased in all groups (SC, 4.7 ± 1.1 mg/kg/min; PF, 4.8 ± 0.8 mg/kg/min; and OF, 4.2 ± 0.4 mg/kg/min; Figure 4C). Infusion of the CPT1A inhibitor icv failed to significantly alter the levels of glucoregulatory hormones (Table 1) and the rate of glucose uptake (Supplemental Figure 4). On the other hand, this intervention markedly suppressed liver glucose production (Figure 4D and Supplemental Figure 4), and this effect entirely accounted for the effect of central inhibition of fat oxidation on glucose metabolism in all groups.

Glucose production represents the net contribution of gluconeogenesis and glycogenolysis. However, a portion of glucose entering the liver via phosphorylation is also a substrate for dephosphorylation via glucose-6-phosphatase (G6Pase, encoded in rodents by the G6pc gene), creating a futile (glucose) cycle. To delineate the mechanisms by which central inhibition of lipid oxidation modulates liver glucose homeostasis, we estimated the in vivo flux through G6Pase and the relative contribution of glucose cycling, gluconeogenesis, and glycogenolysis to glucose output (Figure 4, E and F, Supplemental Figure 4, and Supplemental Table 1). Central CPT1A inhibition markedly and similarly decreased glucose cycling (Supplemental Figure 4) and the flux through G6Pase (Figure 4E) in parallel to its effects on glucose production (Supplemental Figure 4) in SC, PF, and OF rats. The decrease in glucose production was accounted for by a marked inhibition of gluconeogenesis (Figure 4F) as well as by a more modest decrease in the rate of glycogenolysis (Supplemental Figure 4).

We next assessed the effect of central inhibition of fat oxidation on the expression of G6pc and phosphoenolpyruvate carboxykinase, encoded by the Pck1 gene. Real-time PCR analyses revealed that icv administration of a CPT1A inhibitor markedly decreased liver G6pc and Pck1 mRNA levels (Figure 4, G and H). Thus the decreases in the in vivo flux through G6Pase and gluconeogen-
Table 2
Molecular inhibition of hypothalamic CPT1A: general characteristics before and during pancreatic insulin clamp

<table>
<thead>
<tr>
<th>SC pair-fed vector</th>
<th>SC CPT1A-Ribo</th>
<th>OF pair-fed vector</th>
<th>OF CPT1A-Ribo</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>4</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Basal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>293 ± 7</td>
<td>289 ± 8</td>
<td>307 ± 6</td>
</tr>
<tr>
<td>Food intake (kcal)</td>
<td>54</td>
<td>56 ± 3</td>
<td>85</td>
</tr>
<tr>
<td>Glucose (mM)</td>
<td>8.1 ± 2</td>
<td>8.2 ± 0.3</td>
<td>8.2 ± 0.5</td>
</tr>
<tr>
<td>Insulin (ng/ml)</td>
<td>1.2 ± 0.6</td>
<td>1.1 ± 0.2</td>
<td>1.4 ± 0.4</td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>1.3 ± 0.2</td>
<td>0.9 ± 0.2</td>
<td>1.4 ± 0.4</td>
</tr>
<tr>
<td>FFA (mM)</td>
<td>0.6 ± 0.2</td>
<td>0.6 ± 0.1</td>
<td>0.7 ± 0.1</td>
</tr>
<tr>
<td>Clamp</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (mM)</td>
<td>7.6 ± 0.3</td>
<td>7.8 ± 0.2</td>
<td>7.5 ± 0.4</td>
</tr>
<tr>
<td>Insulin (ng/ml)</td>
<td>0.5 ± 0.1</td>
<td>0.6 ± 0.1</td>
<td>0.5 ± 0.1</td>
</tr>
</tbody>
</table>

Data are means ± SEM. The values during clamp represent steady-state levels. In this experiment, the food intake in the vector group was matched to that of CPT1A-Ribo group. Food intake and body weight were measured at the begin of the clamp. FFA, free fatty acids.

Discussion
Type 2 diabetes and obesity are classical examples of diseases caused by gene/environment interactions (25). Secular changes in our lifestyle that include increases in caloric intake and longer time spent performing sedentary activities precipitate their phenotypic manifestations by acting on a genetic/familiar predisposition (26, 27). The hypothalamus is emerging as a critical site for the integration of nutritional, endocrine, and neural cues signaling the body’s metabolic and nutritional status. These signals should normally activate a negative feedback loop between the availability of nutrients and their intake and metabolism (10, 13, 15, 16, 18, 24, 28, 29). It is therefore logical to postulate that a rapid onset of hypothalamic resistance to multiple signals, such as leptin, insulin, and fatty acids, could contribute to the susceptibility to weight gain and insulin resistance in predisposed individuals and animals. In this regard, central resistance to the behavioral and metabolic effects of each of these circulating factors has been reported in various animal models of diet-induced obesity and insulin resistance (30–33). Taken together, these observations raise the possibility that the disruption of a critical component within this regulatory loop confers susceptibility to diet-induced obesity and insulin resistance. Indeed, acquired defects within this regulatory loop have been described in various rodent models of established diet-induced obesity. These experiments have largely focused on the development of leptin resistance that is due partly to defective transport of the hormone across the blood-brain barrier (30, 32) and partly to defective leptin signaling, particularly in the arcuate nuclei of the hypothalamus (23, 30, 31).
We as well as others have also focused on the initial phase in the development of diet-induced obesity and insulin resistance in rats in the hope of identifying early events that may be causative for the establishment of the phenotype (20, 21, 34). These studies have revealed that when Sprague-Dawley rats are exposed to a highly palatable (lard-enriched) diet, they rapidly double their caloric intake, acquire severe hepatic insulin resistance, and fail to respond to the systemic administration of leptin (20) and the central administration of the LCFA oleic acid (21). The latter finding led us to the hypothesis that a rapid impairment in hypothalamic nutrient sensing plays an important role in the onset of obesity and insulin resistance in this model. To begin examining this postulate, we needed to address the following 2 critical questions: *Is the hypothalamic sensing of circulating lipids impaired following short-term overfeeding?* We have recently shown that lipid infusion designed to double the circulating levels of LCFA leads to a doubling of the levels of esterified LCFA in the MBH (16). Furthermore, when the local esterification of LCFA is pharmacologically inhibited, an increase in the availability of lipids fails to promote the accumulation of LCFA-CoAs within the MBH and leads to severe disruption of liver glucose homeostasis (16). Using a similar lipid-infusion protocol, here we demonstrate that doubling the circulating levels of LCFA induced hyperglycemia and failed to increase the levels of LCFA-CoAs in the MBH of OF rats. This appears to be due to the increased utilization of LCFA-CoAs in the MBH mediated by an increase in the in vivo activity of CPT1, which is in turn mediated at least in part by decreased malonyl-CoA levels.

*Is the restoration of hypothalamic lipid sensing sufficient to normalize energy and glucose homeostasis in this model?* The above findings gave us an opportunity to test the role of defective sensing of lipids in the hypothalamus in the development of obesity and hepatic insulin resistance through a classic reconstitution experiment. Since
pharmacologic or molecular inhibition of CPT1A activity in the hypothalamus can selectively increase MBH LCFA-CoA levels (18), we used these experimental approaches in order to evaluate the levels of LCFA-CoAs in the MBH of OF rats. Indeed, curtailting the rate of oxidative lipid metabolism within the hypothalamus was sufficient to restore hypothalamic lipid sensing and to dramatically decrease food intake and glucose production in OF rats.

An important role of hypothalamic lipid metabolism in the regulation of energy homeostasis is also supported by numerous reports on the potent effects of inhibitors of fatty acid synthase (FAS) on body weight, food intake, and substrate oxidation (11, 13, 35–38). While the precise mechanism by which systemic or central administration of the FAS inhibitor C75 leads to multiple effects on energy balance remains to be established, it is noteworthy that the anorectic effects of the systemic administration of C75 is preserved in genetic (39) and acquired rodent models of obesity (11, 35, 36). Since the hypothalamic accumulation of malonyl-CoA, a potent inhibitor of CPT1 activity, has been implicated in the central effects of C75 (38), these findings appear to be consistent with the preserved effects of the direct pharmacologic or molecular inhibition of CPT1A inhibition in OF rats.

Our findings suggest that the compounded effects of a decrease in malonyl-CoA levels and an increase in CPT1 activity negate lipids’ ability to increase the cellular levels of LCFA-CoAs in the MBH. Most importantly, the observation that restoring the hypothalamic levels of esterified fatty acids to those observed in normal rats is sufficient to curtail both feeding behavior and glucose production indicates that hypothalamic lipid sensing plays a critical role in the maintenance of energy and glucose homeostasis. Since severe leptin resistance is also a feature of this model (20), one has to postulate that the MBH levels of LCFA-CoAs either lie downstream of the leptin signaling pathway (14) or can exert their anorexigenic and metabolic actions even in the presence of impaired leptin signaling.

In conclusion, this model of diet-induced obesity and insulin resistance displayed defective adaptation to an increase in lipid availability coupled with a severe impairment in the hypothalamic sensing of lipids. Importantly, restoration of hypothalamic lipid sensing by central inhibition of fatty acid oxidation was sufficient to normalize feeding behavior and glucose homeostasis. Further studies will be required to establish the critical role of this biochemical pathway in nutrient sensing in other animal models and in humans.

Methods
Animal preparation. We studied 147 ten-week-old male Sprague-Dawley rats (Charles River Laboratories). Rats were housed in individual cages and subjected to a standard light-dark cycle. Three weeks prior to the in vivo studies, rats underwent stereotaxic surgery to indwell a single catheter in the third cerebral ventricle (10, 40) or bilateral catheters into the MBH (41). One week later, indwelling catheters were placed in the internal jugular vein and carotid artery (10, 40). SC animals were fed standard chow (catalog no. 5001; Purina Mills Inc.), and OF animals were fed a highly palatable high-fat diet (catalog no. 9389; Purina Mills Inc.) that was genetically (39) and acquired rodent models of obesity (11, 35–38). While the precise mechanism by which systemic or central administration of the FAS inhibitor (catalog no. 5001; Purina Mills Inc.) was that generated by supplementing the SC diet with 10% lard (Supplemental Table 3). The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee of the Albert Einstein College of Medicine.

Feeding behavior studies. This experimental protocol was designed to examine the acute effect of central inhibition of CPT1A on food intake in experimental groups SC and OF. SC and OF animals were allowed to eat their diets ad libitum. Rats were adapted to the metabolic cages, and their daily food intake had been constant (changed < 10%) for a minimum of 3 consecutive days preceding the allocation to each group diet. Food intake was measured daily for 3 days after injection.

Pharmacologic inhibition of CPT1A. Following 3 days of ad libitum feeding (Figure 1A, day 0) and 3 hours before the onset of the dark cycle, rats received an icv bolus injection of either CPT1A inhibitor (5 and 25 pmol) or control compound (25 pmol) (Supplemental Figure 1). Molecular inhibition of CPT1A. Following 2 days of ad libitum feeding (Fig 1A, day 0), rats received an icv bolus injection of CPT1A-Ribo or pTarget vector alone (Supplemental Figure 1) (18).

Conditioned taste aversion. Conditioned taste aversion was tested as described previously (42). Rats received icv CPT1 inhibitor (50 pmol/5 μl), i.p. LiCl (22 mg/kg) as the positive control, or icv artificial cerebrospinal fluid. Data are expressed as a preference ratio of saccharin intake to total fluid intake (i.e., saccharin plus water intake).

Pharmacologic inhibition of CPT1A. At t = 0 minutes, we began a continuous i.v. infusion of either a reversible CPT1A inhibitor or its inactive stereoisomer at a rate of 50 pmol/h in a volume of 5 μl (Supplemental Figure 1C), and maintained it throughout the study (6 hours). For the pancreatic clamp performed during lipid infusion, the CPT1A inhibitor or the control compound (1 mM solution) were delivered in the MBH for 6 hours at a rate of 0.33 μl/h. CPT1A inhibitor and control compound were dissolved in artificial cerebrospinal fluid (Harvard Apparatus).

Molecular inhibition of CPT1A. Two days before the pancreatic insulin clamp, rats received the icv injection of CPT1A-Ribo or vector control. Controls were pair-fed with the rats receiving CPT1A-Ribo.

Clamp studies. At 120 minutes, a primed continuous infusion of [3-14C]-lactate (40 μCi bolus, 0.4 μCi/min; New England Nuclear) purified by high-performance liquid chromatography (HPLC) was started and continued for the duration of the study (15, 18, 24). Samples for determination of [3-14C]-glucose-specific activity were obtained at 10-minute intervals. Finally, a pancreatic insulin clamp (15, 18, 24) was initiated at 240 minutes and lasted for 2 hours. This procedure involved the infusion of somatostatin (3 μg/kg/min), insulin (1 μU/kg/min). Additionally, a variable infusion of a 25% glucose solution was started and periodically adjusted to clamp the plasma glucose concentration at approximately 8 mM.

Lipid infusion studies. At 120 minutes, rats received i.v. saline or 20% intralipid (mixed with 20 U/ml of heparin, 0.4 ml/h) and [3-14C]-glucose for 4 hours (16). A pancreatic clamp was performed in the final 2 hours as described above. Intralipid was purchased from Baxter and consisted of 26% oleic acid (18:1), 50% linoleic acid (18:2), 9% linolenic acid (18:3), 10% palmitic acid (16:0), and 3.5% stearic acid (18:0).

Analytical procedures. Plasma samples for determination of plasma free fatty acid, insulin, and leptin concentrations were obtained at 30-minute intervals during the study. Ten minutes before the end of the studies, [U-13C]-lactate (20 μCi bolus; 1.0 μCi/min; New England Nuclear) was administered to determine the contribution of gluconeogenesis to the pool of hepatic G6P (43). At the end of the clamp studies rats were anesthetized, and tissue samples were freeze-clamped in situ with aluminum tongs pre-cooled in liquid nitrogen. All tissue samples were stored at −80°C for subsequent analysis.

CPT1A-Ribo plasmid. CPT1A-Ribo plasmid (Supplemental Figure 1B) was prepared and delivered as previously described (18). Briefly, endotoxin-free plasmid DNA was complexed with polyethylengamine (Sigma-Aldrich) (44) and injected i.v. as a single bolus. Control studies used pTarget (Stratagene) plasmid DNA (Vector Laboratories).

LCE-COAs measurements. LCE-CoAs were extracted from mediobasal hypothalamic wedges and measured by HPLC as previously described (45).

MBH malonyl-CoA. The MBH was sampled, and malonyl-CoA was extracted and measured by a modification of an HPLC method previously described (46).
Acyl-CoA hydrolase activity assay. Rat arcuate extracts (approximately 5 μg of protein) were incubated in the presence of 3.7 kBq [66 μM] of \[^{14}C\]-palmitoyl-CoA at 37°C for 25 μl of reaction buffer (50 mM Tris-HCl, pH 7.0, 1 mM CaCl₂, BSA 1 mg/ml). After 1-hour incubation the reactions were terminated by chilling on ice. Free \[^{14}C\]-palmitate was extracted with n-hexane and measured by scintillation counting. Activity is expressed as cpm of \[^{14}C\]-palmitate/μg protein.

Quantitation of CPT1A and CPT1B mRNA. Total RNA was isolated with Trizol (Invitrogen Corp.) from individual hypothalamic nuclei. Single-stranded cDNA synthesis, and quantitative expression for CPT1A and CPT1B was measured by quantitative RT-PCR as described previously (18). The copy number of each transcript was measured against a copy number standard curve of cloned target templates. Expression of each transcript was normalized to the copy number for β-actin.

Göpel and Pck1 expression. Liver Göpel and phosphoenolpyruvate carboxykinase (Pck1) mRNA abundance were assessed by quantitative real-time PCR as previously described (16, 24). The number of each transcript was derived from a standard curve of cloned target templates. Expression of each transcript was normalized to the copy number for Gapdh.

Received for publication August 19, 2005, and accepted in revised form January 17, 2006.

Address correspondence to: Luciano Rossetti, Diabetes Research Center, Albert Einstein College of Medicine, 1300 Morris Park Avenue, New York, New York 10461, USA. Phone: (718) 430-4118; Fax: (718) 430-8557; E-mail: rossetti@aecom.yu.edu.

Acknowledgments

We wish to thank B. Liu, Y. Wang, C. Baveghems, and S. Gaweda for expert technical assistance. This work was supported by grants from the National Institutes of Health (DK 48321, DK 45024, and AG 21654 to L. Rossetti), the AECOM Diabetes Research & Training Center (DK 20541), and the Skirball Foundation. S. Obici is the recipient of a Junior Faculty Award from the American Diabetes Association. T.K.T. Lam is supported by a Training Grant from the National Institute on Aging (T32-AG023475). A. Pocai and E.D. Muse are supported by the American Diabetes Association.